Clinical Trial: Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07888816) titled 'Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers' on Oct. 08.

Brief Summary: The ORION study will evaluate a novel treatment approach for patients with recurrent, metastatic, oligometastatic, or locoregionally incurable head and neck squamous cell carcinoma (HNSCC). Participants will receive pulsed adaptive radiotherapy delivered in 3 to 5 treatment courses approximately 10 days apart, alongside standard-of-care pembrolizumab with or without chemotherapy. Using advanced imaging and adaptive treatment planning, radiotherapy will be tailored to changes in tumor size and s...